Clearside BioMedical Inc (CLSD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Clearside BioMedical Inc (CLSD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH378786D
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that provides development and commercialization of therapeutics. The company offers administration of active ingredients such as SCS injection of CLS-TA, SCS injection of CLS-TA and SCS injection of anti-VEGF compound or compound with dual anti-VEGF and anti-PDGF activity. Its products indicate macular edema associated with non- infectious uveitis, macular edema associated with retinal vein occlusion and wet age-related macular degeneration applications. The company also provides business development contract, license agreements and contract manufacturing services. It operates through its offices in Alpharetta and Durham, the US. Clearside is headquartered in Alpharetta, Georgia, the US.

Clearside BioMedical Inc (CLSD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clearside BioMedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Clearside BioMedical Inc, Medical Devices Deals, 2011 to YTD 2017 10

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Clearside Biomedical Raises USD0.3 Million in Venture Financing 13

Clearside Biomedical Raises USD20 Million in Series C Financing 13

Clearside Biomedical Raises USD16 Million in Series B Venture Financing 14

Clearside Biomedical Raises USD8 Million In Venture Financing 15

Clearside Biomedical Raises Additional Funds In Series A Financing 17

Partnerships 18

Clearside Biomedical Enters into Agreement with EyeKor 18

Santen Expands Research Agreement with Clearside Biomedical 18

Santen Enters Into Research Agreement With Clearside Biomedical 19

Licensing Agreements 20

NovaMedica Enters into Licensing Agreement with Clearside Biomedical 20

Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 21

Equity Offering 22

Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares 22

Clearside BioMedical Prices Public Offering of Shares for USD36 Million 23

Clearside Biomedical Raises USD50.4 Million in IPO 25

Clearside BioMedical Inc-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

May 10, 2017: Clearside Biomedical Announces First Quarter 2017 Financial Results and Provides Corporate Update 30

Mar 14, 2017: Clearside Biomedical Announces Fourth Quarter And Full Year 2016 Financial Results 32

Nov 09, 2016: Clearside Biomedical Announces Third Quarter 2016 Financial Results and Provides Corporate Update 34

Aug 11, 2016: Clearside Biomedical Reports Second Quarter 2016 Financial Results 36

Corporate Communications 37

Jan 04, 2017: Clearside Biomedical Appoints Richard Beckman, M.D., as Chief Medical Officer 37

Dec 14, 2016: Clearside Biomedical Added to NASDAQ Biotechnology Index 38

Feb 29, 2016: Clearside Biomedical Announces Appointment of Richard J. Croarkin to the Board of Directors 39

Product News 40

Nov 15, 2016: Clearside Biomedical Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata in Diabetic Macular Edema 40

Clinical Trials 41

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 41

Aug 03, 2016: Clearside Biomedical to Present Data from Phase 2 (DOGWOOD) Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis at the 2016 ASRS Annual Meeting 42

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 43

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 44

Jan 05, 2016: Clearside Biomedical Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46

List of Figures

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Clearside BioMedical Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Key Facts 1

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clearside BioMedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clearside BioMedical Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Clearside BioMedical Inc, Medical Devices Deals, 2011 to YTD 2017 10

Clearside BioMedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Clearside Biomedical Raises USD0.3 Million in Venture Financing 13

Clearside Biomedical Raises USD20 Million in Series C Financing 13

Clearside Biomedical Raises USD16 Million in Series B Venture Financing 14

Clearside Biomedical Raises USD8 Million In Venture Financing 15

Clearside Biomedical Raises Additional Funds In Series A Financing 17

Clearside Biomedical Enters into Agreement with EyeKor 18

Santen Expands Research Agreement with Clearside Biomedical 18

Santen Enters Into Research Agreement With Clearside Biomedical 19

NovaMedica Enters into Licensing Agreement with Clearside Biomedical 20

Clearside Biomedical Enters into Licensing Agreement with Emory University and GTRC 21

Clearside Biomedical Plans to Raise up to USD50 Million in Public Offering of Shares 22

Clearside BioMedical Prices Public Offering of Shares for USD36 Million 23

Clearside Biomedical Raises USD50.4 Million in IPO 25

Clearside BioMedical Inc, Key Competitors 27

Clearside BioMedical Inc, Key Employees 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Clearside BioMedical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16145
Site License
USD 500 INR 32290
Corporate User License
USD 750 INR 48435

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com